secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001104659-26-024121
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports FY2025 net loss of $55.8M; cash $41.8M; SIM0505 data expected Q2 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities at Dec 31, 2025: $41.8M, down from $68.6M a year ago.
- Net loss for FY2025: $55.8M, roughly flat vs $55.7M in FY2024; R&D expenses rose to $44.9M.
- SIM0505 (CDH6 ADC) Phase 1 dose escalation data and dose optimization start in ovarian cancer both expected Q2 2026.
- LNCB74 (B7-H4 ADC) Phase 1 dose escalation update anticipated in second half of 2026.
- Company expects current resources to fund operations into first half of 2027 through proof-of-concept for SIM0505.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926024121/0001104659-26-024121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926024121/nxtc-20260305x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-024121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer